trending Market Intelligence /marketintelligence/en/news-insights/trending/iuSSeU1VtXMOvokbfATuMg2 content esgSubNav
In This List

Adaptimmune's T-cell therapy shows efficacy, safety in pilot study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Adaptimmune's T-cell therapy shows efficacy, safety in pilot study

Adaptimmune Therapeutics plc's NY-ESO SPEAR T-cell therapy showed "promising efficacy and acceptable safety" in a pilot study of multiple myeloma patients.

Investigators observed overall response rates of 76% at 100 days and 44% at one year, with a median response duration of at least 12 months and a median predicted overall survival of about 3 years.

No fatal adverse events were reported, with the most common adverse events being generally expected in the patient population.

The company said a follow-up study combining the NY-ESO SPEAR T-cell therapy with Keytruda will transition to GlaxoSmithKline plc, which recently acquired the rights to the program.